Akebia extends vadadustat supply agreement with STA to 2029

Akebia Therapeutics, Inc.

Amendment #2 extends Supply Agreement term to April 2, 2029 (five additional years).
Agreement covers manufacturing of vadadustat drug substance for commercial purposes.
Volume-based pricing structure was amended; no financial terms disclosed.
Original Supply Agreement dated April 2, 2020, previously amended April 15, 2021.
Contract manufacturer STA Pharmaceutical Hong Kong Limited.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Akebia Therapeutics, Inc. amended Amendment #2 to the Supply Agreement with STA Pharmaceutical Hong Kong Limited (effective 2024-04-15).

Action: amendment
Agreement: supply
Counterparty: STA Pharmaceutical Hong Kong Limited
Effective: 2024-04-15

Exact text from the filing

(the “Company”) entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation (“STA”), as amended on April 15, 2021 (as amended, the “Supply Agreement”), under which STA manufactures vadadustat drug substance (“Product”) for the Company’s commercial purposes.

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.